Search

Search Results

• 

  Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation

  Tommaso Sacquegna, Anna Zaniboni, Andrea Rubboli, Gaetano Procaccianti, Michela Crisci, Fabiola Maioli, Giorgia Arnone, Giuseppe Di Pasquale

  314-322

  15-12-2015

  1914

  PDF: 881

  HTML: 1227

• Acute severe renal failure in a patient receiving apixaban: a case report

  Attilia Maria Pizzini, Chiara Fantoni, Stefania Zaccaroni, Mauro Silingardi

  09-04-2024

  425

  PDF: 326

  HTML: 67

• Assessment and predictors of inappropriate dose of direct oral anticoagulants

  Mosaad O. Almegren

  09-01-2024

  722

  pdf: 347

  HTML: 113
• 

  Apixaban

  Gianluca Airoldi, Mauro Campanini

  128-134

  07-03-2013

  1106

  PDF: 1760
• 

  Newer non-vitamin K-antagonist direct oral anticoagulants in acute coronary syndromes

  Andrea Rubboli

  22-28

  24-12-2013

  952

  PDF: 714
• 

  Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows

  Luca Masotti, Mario Di Napoli, Walter Ageno, Davide Imberti, Daniel Godoy, Grazia Panigada, Niccolò Napoli, Giancarlo Landini, Roberto Cappelli, Ido Iori, Domenico Prisco, Giancarlo Agnelli

  153-169

  23-10-2012

  1625

  PDF: 1924
• 

  Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics

  Luca Masotti, Mauro Campanini

  1-7

  24-12-2013

  9498

  PDF: 2677
• 

  New oral anticoagulants: key messages for clinicians

  Matteo Giorgi-Pierfranceschi, Chiara Cattabiani, Francesco Dentali

  74-84

  24-12-2013

  1236

  PDF: 844
• 

  The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy

  Luca Masotti, Giancarlo Landini, Grazia Panigada

  48-58

  24-12-2013

  1322

  PDF: 900
• 

  New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis

  Mauro Silingardi

  65-70

  24-12-2013

  1311

  PDF: 922
• 

  Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation

  Luca Masotti, Mario Di Napoli, Walter Ageno, Davide Imberti, Cecilia Becattini, Maurizio Paciaroni, Daniel Augustin Godoy, Roberto Cappelli, Giancarlo Landini, Grazia Panigada, Ido Iori, Domenico Prisco, Giancarlo Agnelli

  8-21

  24-12-2013

  1271

  PDF: 835
• 

  Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists

  Giancarlo Landini, Luca Masotti

  41-47

  24-12-2013

  881

  PDF: 773

• Patent foramen ovale and stroke: a possible association with deep vein thrombosis

  Raffaele Natale, Luca Maria Capece, Sofia Donnarumma, Pasquale Madonna, Carolina Bologna, Domenico Birra, Antonietta De Sena, Marina Lugarà, Claudio De Luca, Mariavittoria Guerra, Gabriella Oliva, Fabio Granato Corigliano, Paolo Tirelli, Vincenzo Nuzzo

  29-10-2024

  622

  PDF: 189

  HTML: 21
• 

  Monitoring strategies for patients treated with the new oral anticoagulants and the need for laboratory evaluation of hemostasis

  Andrea Fontanella, Pierpaolo Di Micco

  59-64

  24-12-2013

  903

  PDF: 881
• 

  Cryptogenic strokes and embolic strokes of unknown source: lights and shadows of a new construct

  Marco Masina

  171-174

  30-09-2016

  1377

  PDF: 836

  HTML: 635
• 

  A dangerous adverse event in the use of dabigatran

  Manuel Monti, Giovanni Maria Vincentelli, Francesco Borgognoni, Giuseppe Murdolo, Feliciano Menghini

  250-251

  09-11-2015

  1556

  PDF: 862

  HTML: 253
• 

  The treatment of venous thromboembolism with new oral anticoagulants

  Davide Imberti

  29-35

  24-12-2013

  1033

  PDF: 811
• 

  Cryptogenic stroke

  Michele Stornello, Roberto Cappellani, Giuseppe Micieli, Simona Sacco, Stefano Spolveri, Roberto Sterzi, Danilo Toni, Antonio Carolei

  185-194

  30-09-2016

  1830

  PDF: 1070

  HTML: 581
• 

  How artificial intelligence during the pandemic modified the role of a biomarker as d-dimer

  Pierpaolo Di Micco, Francesca Futura Bernardi, Giovanni Maria Fusco, Alessandro Perrella

  20-11-2023

  810

  PDF: 252

  HTML: 28
• 

  Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia

  Pasquale Madonna, Anna Guida, Maria Gabriella Coppola, Paolo Tirelli, Ernesto Grasso

  18-03-2021

  1017

  PDF: 499

  HTML: 51
• 

  Optimal duration of anticoagulant therapy in patients with venous thromboembolism

  Gualtiero Palareti

  235-244

  14-09-2018

  1429

  PDF: 1731

  HTML: 257
• 

  Stroke prevention in atrial fibrillation: findings from Tuscan FADOI Stroke Registry

  Luca Masotti, Rinaldo Innocenti, Stefano Spolveri, Irene Chiti, Grazia Panigada, Cristiana Seravalle, Giancarlo Landini, Alberto Fortini, Rino Migliacci, Raffaele Laureano, for Tuscan FADOI Stroke Registry Investigators

  134-140

  12-06-2014

  1517

  PDF: 1187

  Appendix: 563

  HTML: 622
• 

  Young FADOI and gender medicine: sex gender differences in cardiovascular disease

  Tiziana Ciarambino, Miriam Gino, Paola Gnerre, Elena Barbagelata, Nunzia Barone, Francesca Saladini, Federica Lorenzi, Marta Zanon, Maria Cristina Pasquini, Cecilia Politi

  23-31

  20-03-2018

  2548

  PDF: 1081

  HTML: 464
• 

  Characteristics and clinical management of acute pulmonary embolism in real world: findings from TUSCAN-PE study

  Luca Masotti, Filippo Pieralli, Grazia Panigada, Francesco Corradi, Rino Migliacci, Salvatore Lenti, Alessandro Tafi, Carlo Nozzoli, Giancarlo Landini, for TUSCAN-PE Investigators

  125-133

  03-06-2014

  2055

  PDF: 1250

  Appendix: 1081

  HTML: 747
• 

  Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit

  Marco Masina, Annalena Cicognani, Carla Lofiego, Simona Malservisi, Riccardo Parlangeli, Alessandro Lombardi

  202-206

  30-09-2016

  1557

  PDF: 802

  HTML: 803